317 related articles for article (PubMed ID: 28034844)
1. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
Le Couteur DG; Hunter S; Brayne C
BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
[No Abstract] [Full Text] [Related]
2. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
Gamage KK; Kumar S
J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
[No Abstract] [Full Text] [Related]
3. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
[TBL] [Abstract][Full Text] [Related]
4. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
5. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
Patel KR
Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
[No Abstract] [Full Text] [Related]
6. Treatments for Alzheimer's disease emerge.
Selkoe DJ
Science; 2021 Aug; 373(6555):624-626. PubMed ID: 34353940
[No Abstract] [Full Text] [Related]
7. Landmark Alzheimer's drug approval confounds research community.
Mullard A
Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
[No Abstract] [Full Text] [Related]
8. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for Alzheimer's disease].
Falkentoft AC; Hasselbalch SG
Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
[TBL] [Abstract][Full Text] [Related]
10. Amyloid plaques are still main target for Alzheimer's drugs.
Hawkes N
BMJ; 2016 Jan; 352():i214. PubMed ID: 26762356
[No Abstract] [Full Text] [Related]
11. Aducanumab: look before leaping.
Perlmutter JS
Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
[No Abstract] [Full Text] [Related]
12. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
Shin J
Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001
[No Abstract] [Full Text] [Related]
13. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
Saxena U
Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
[TBL] [Abstract][Full Text] [Related]
14. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
Rabinovici GD
N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
[No Abstract] [Full Text] [Related]
15. NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost.
Underwood E
Science; 2015 Jul; 349(6247):464. PubMed ID: 26228122
[No Abstract] [Full Text] [Related]
16. Alzheimer's disease: beta-amyloid hypothesis strengthened!
Gerlai R
Trends Neurosci; 2001 Apr; 24(4):199. PubMed ID: 11249992
[No Abstract] [Full Text] [Related]
17. Why aducanumab is important.
Cummings J
Nat Med; 2021 Sep; 27(9):1498. PubMed ID: 34413516
[No Abstract] [Full Text] [Related]
18. Sixty seconds on . . . solanezumab.
Hawkes N
BMJ; 2016 Nov; 355():i6389. PubMed ID: 27899350
[No Abstract] [Full Text] [Related]
19. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
Salloway S; Sperling R; Brashear HR
N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24724181
[No Abstract] [Full Text] [Related]
20. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.
de la Torre JC
N Engl J Med; 2014 Apr; 370(15):1459-60. PubMed ID: 24716689
[No Abstract] [Full Text] [Related]
[Next] [New Search]
